A randomized controlled trial on meropenem versus imipenem/cilastatin in the treatment of bacterial infection

Chinese Journal of Antibiotics

Volumn 26, Issue 2, 2001, Pages 118-122

  Xiao Ju, L ^a   Nan, X ^a   Jia, M ^a   Li, Z ^a   De Rong, L ^a   Dun Gong, Q ^a   Ze Rong, C ^a   Ru Jia, Y ^a   Chun Jiang, S ^a   Zhong Hui, Z ^a  

^a FIRST AFFILIATED HOSPITAL   (China)

Author keywords

Bacterial infection; Imipenem cilastatin; Meropenem; Randomized controlled trial

Indexed keywords

BETA LACTAMASE; CILASTATIN PLUS IMIPENEM; MEROPENEM;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0035001727     PISSN: 10018689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Prospective, randomised, multicenter study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections
2. Imipenem/cilastatin versus meropenem in patients with intra-abdominal infections: Results of a prospective, randomized, multicenter trial
3. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: A randomized study. Meropenem lower respiratory infection group